Skincare firm Galderma posts 25.5% sales jump driven by US market

Skincare company Galderma posts 25.5% sales leap, driven by US market

Galderma’s First-Quarter Performance and Market Outlook

ZURICH, April 23 (Reuters) - Swiss skincare company Galderma said on Thursday that first-quarter sales jumped 25.5% in constant-currency terms to $1.47 billion and signalled it could manage the impact of U.S. tariffs in 2026.

Strong U.S. Market Demand

The Zug-based group was buoyed by strong demand in the U.S., where sales surged 41.5% year on year in the January–March period.

Company Statement on Growth and Guidance

"Based on the strong start to the year, the guidance is increasingly being de-risked with confidence to navigate a volatile environment," Galderma said in a statement.

The results lifted the company's shares, which were up more than 6% shortly before 0900 GMT.

Managing U.S. Tariffs and Financial Outlook

Galderma, which was listed on the Swiss stock exchange just over two years ago, said its exposure to U.S. tariffs was expected to remain "manageable" this year.

CEO Insights on Product Performance

Chief Executive Flemming Ornskov said sales of its injectable dermatitis treatment Nemluvio were very strong, with U.S. demand for dermatological skincare products particularly robust on Amazon and other e-commerce platforms.

Market Share and Tariff Refunds

Ornskov told Reuters that Galderma was gaining market share in the U.S., and was monitoring how companies handled potential refunds linked to tariffs struck down by the U.S. Supreme Court.

Any amounts owed would not materially change the group's 2026 financial outlook, he said.

Impact of Global Events on Operations

Galderma has so far managed to mitigate the impact of the conflict in the Middle East, Ornskov said.

Supply Chain Stability

"We haven't really seen an impact on our supply costs at this stage," he said. "And we have a very diverse supply chain."

(Reporting by Dave Graham. Editing by Ludwig Burger and Mark Potter)